-
公开(公告)号：US20210322533A1
公开(公告)日：2021-10-21
申请号：US17261345
申请日：2019-07-19
Applicant: Biological E Limited
Inventor： Veerapandu Sangareddy , Rajendar Burki , Rajan Sriraman , Ramesh Venkat Matur , Narender Dev Mantena , Mahima Datla
IPC: A61K39/09
Abstract: The present invention relates to vaccine formulations comprising preservative systems. More particularly, the present invention relates to preservative systems for vaccine formulations which is free of thiomersal, and comprising 2-phenoxyethanol and at least one other preservative selected from m-cresol, benzyl alcohol, phenol and benzoic acid.
-
公开(公告)号：US20190240308A1
公开(公告)日：2019-08-08
申请号：US15772771
申请日：2016-06-21
Applicant: BIOLOGICAL E LIMITED
Inventor： Ramesh Venkat Matur , Nagarajan Thirumeni , Rajendar Burki , Narender Dev Mantena , Mahima Datla
CPC classification number: A61K39/092 , A61K9/0019 , A61K9/0043 , A61K9/0053 , A61K39/39 , A61K47/6415 , A61K47/646 , A61K2039/55505 , A61K2039/6037 , A61P31/04
Abstract: The present invention relates to a multivalent Pneumococcal conjugate vaccine (PCV) composition comprising: 1) at least 12 capsular polysaccharides selected from serotypes 1, 3, 4, 5, 6B, 7F, 9N, 9V, 15B, 14, 18C, 19A, 19F, 22F, 23F and 33F of S. pneumoniae activated with CDAP and conjugated to carrier protein selected from CRM197, pneumococcal surface protein A (PspA), pneumococcal adhesin protein (PsaA) or combination thereof and 2) a pharmaceutically acceptable carrier, wherein the composition does not contain capsular polysaccharide from serotype 6A.
-
公开(公告)号：US12048739B2
公开(公告)日：2024-07-30
申请号：US17278181
申请日：2019-09-23
Applicant: Biological E Limited
Inventor： Rajendar Burki , Vivek Babu Kandimalla , Rajan Sriraman , Ramesh Venkat Matur , Narender Dev Mantena , Mahima Datla , Veerapandu Sangareddy
CPC classification number: A61K39/092 , A61K31/715 , A61K47/62 , C08B37/0003 , A61K2039/6037 , A61K2039/70
Abstract: The invention relates to capsular polysaccharides of Streptococcus pneumoniae. More specifically, the present invention relates to sized and purified capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C & 35B and process for their preparation.
-
公开(公告)号：US20210346488A1
公开(公告)日：2021-11-11
申请号：US17278181
申请日：2019-09-23
Applicant: Biological E Limited
Inventor： Rajendar Burki , Vivek Babu Kandimalla , Rajan Sriraman , Ramesh Venkat Matur , Narender Dev Mantena , Mahima Datla , Veerapandu Sangareddy
IPC: A61K39/09 , A61K47/62 , A61K31/715 , C08B37/00
Abstract: The invention relates to capsular polysaccharides of Streptococcus pneumoniae. More specifically, the present invention relates to sized and purified capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C & 35B and process for their preparation.
-
Patent Agency Ranking
公开(公告)号：US20240325516A1
公开(公告)日：2024-10-03
申请号：US18741232
申请日：2024-06-12
Applicant: Biological E Limited
Inventor： Rajendar Burki , Vivek Babu Kandimalla , Rajan Sriraman , Ramesh Venkat Matur , Narender Dev Mantena , Mahima Datla , Veerapandu Sangareddy
IPC: A61K39/09 , A61K31/715 , A61K39/00 , A61K47/62 , C08B37/00
CPC classification number: A61K39/092 , A61K31/715 , A61K47/62 , C08B37/0003 , A61K2039/6037 , A61K2039/70
Abstract: The invention relates to capsular polysaccharides of Streptococcus pneumoniae. More specifically, the present invention relates to sized and purified capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C & 35B and process for their preparation.
-
6.发明申请公开(公告)号：US20230101892A1
公开(公告)日：2023-03-30
申请号：US18074884
申请日：2022-12-05
Applicant: Biological E Limited
Inventor： Ramesh Venkat Matur , Rajan Sriraman , Deviprasanna Chakka , Satyam Naidu Sureddi , Rajendar Burki , Sreenivasa Rao Ganti , Narender Dev Mantena , Mahima Datla
Abstract: The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following: a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.
-
7.发明授权公开(公告)号：US11547752B2
公开(公告)日：2023-01-10
申请号：US16369933
申请日：2019-03-29
Applicant: BIOLOGICAL E LIMITED
Inventor： Ramesh Venkat Matur , Rajan Sriraman , Deviprasanna Chakka , Satyam Naidu Sureddi , Rajendar Burki , Sreenivasa Rao Ganti , Narender Dev Mantena , Mahima Datla
IPC: A61K39/09 , A61K39/39 , A61K39/385 , A61K9/00 , A61K39/00
Abstract: The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.
-
公开(公告)号：US11147863B2
公开(公告)日：2021-10-19
申请号：US15772771
申请日：2016-06-21
Applicant: BIOLOGICAL E LIMITED
Inventor： Ramesh Venkat Matur , Nagarajan Thirumeni , Rajendar Burki , Narender Dev Mantena , Mahima Datla
Abstract: The present invention relates to a multivalent Pneumococcal conjugate vaccine (PCV) composition comprising: 1) at least 12 capsular polysaccharides selected from serotypes 1, 3, 4, 5, 6B, 7F, 9N, 9V, 15B, 14, 18C, 19A, 19F, 22F, 23F and 33F of S. pneumoniae activated with CDAP and conjugated to carrier protein selected from CRM197, pneumococcal surface protein A (PspA), pneumococcal adhesin protein (PsaA) or combination thereof and 2) a pharmaceutically acceptable carrier, wherein the composition does not contain capsular polysaccharide from serotype 6A.
-
9.发明申请公开(公告)号：US20190224295A1
公开(公告)日：2019-07-25
申请号：US16369933
申请日：2019-03-29
Applicant: BIOLOGICAL E LIMITED
Inventor： Ramesh Venkat Matur , Rajan Sriraman , Deviprasanna Chakka , Satyam Naidu Sureddi , Rajendar Burki , Sreenivasa Rao Ganti , Narender Dev Mantena , Mahima Datla
Abstract: The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.017 seconds)
